Site navigation

Navigation

Lymphoma (follicular non-Hodgkin's) - rituximab (replaced by TA137)

The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma

Summary

This guidance has been updated and replaced by Lymphoma (follicular non-Hodgkin's) - rituximab.


Guidance documents

  • No documents found

Implementing this guidance

  • No documents found

We will consult on our review plans for this guidance in January 2005

About this guidance

Technology appraisals TA37

Issued: March 2002

See related guidance:

See this guidance in practice:

Order printed copies of this guidance